Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan, reported that an open-label, single-arm phase III trial of FP-001 LMIS (leuprolide mesylate) 50 mg in patients with advanced prostate carcinoma achieved its primary efficacy endpoint in 97 percent of the study's participants.